EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer

Ruth Pidsley iD, Dilys Lam, Wenjia Qu, Phillip Stricker iD, James G Kench, Lisa G Horvath, Susan J Clark iD

BJUI Compass · 2024-12 · 5 (12) · 1299-1306

DOI: 10.1002/bco2.445 ↗

At a glance

Journal article in BJUI Compass, published online on 2024-10-30. Written by Ruth Pidsley and 6 co-authors. Institution: Garvan Institute of Medical Research Sydney New South Wales Australia. Cited 7 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY 4.0). Funded by: Cancer Council NSW.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Objectives

We aim to determine the prognostic significance of glutathione S‐transferase Pi 1 DNA methylation ( mGSTP1 ) in two independent prostate cancer cohorts with long‐term clinical follow‐up data. Subjects/Patients and Methods We first re‐examined a published, in‐house whole genome bisulphite sequencing (WGBS) prostate cancer dataset, derived from radical prostatectomy (RP) tissue ( n = 15) with median follow‐up 19.5 years, to confirm and visualise the association between mGSTP1 and patient mortality. To validate prognostic significance, we used a quantitative methylation‐specific head‐loop (MS‐HL) assay to measure mGSTP1 levels in a larger, independent cohort ( n = 186), and performed univariable and multivariable Cox survival analysis.

Results

Re‐analysis of WGBS data showed a significant increase in mGSTP1 in RP samples from patients with lethal versus non‐lethal disease. Subsequent analysis in the larger cohort using the MS‐HL assay confirmed that mGSTP1 was detectable in 97% of RP samples, validating the diagnostic potential of mGSTP1 . Univariable Cox survival analysis revealed a significant association between mGSTP1 levels and biochemical recurrence and metastatic relapse free survival, with a near‐significant association with prostate cancer specific mortality. Notably, multivariable Cox models demonstrated that mGSTP1 did not add independent prognostic value beyond standard clinicopathological features.

Conclusion

Our study supports the importance of DNA methylation as a tissue‐based prostate tumour biomarker. GSTP1 methylation is well established as a diagnostic marker, and in this study, we find that GSTP1 methylation levels are also associated with disease prognosis. Further research is required into the clinical utility of prognostic methylation markers and their functional role in disease progression.

Subjects

Author keywords

DNA methylationGSTP1biomarkerdiagnosticepigeneticsprognosticprostate cancer

Authors and institutions

  • Garvan Institute of Medical Research Sydney New South Wales Australia.
  • School of Clinical Medicine Faculty of Medicine and Health, UNSW Sydney New South Wales Australia.
  • Present address: School of Molecular Sciences The University of Western Australia Crawley Western Australia Australia.
  • Present address: Harry Perkins Institute of Medical Research Nedlands Western Australia Australia.
  • Department of Urology St. Vincent's Sydney New South Wales Australia.
  • St Vincent's Prostate Cancer Research Centre Sydney New South Wales Australia.

ORCID profiles: Ruth Pidsley, Phillip Stricker, Susan J Clark

Funding

  • Cancer Council NSW

Cite

APA

Pidsley, R., Lam, D., Qu, W., Stricker, P., Kench, J. G., Horvath, L. G., & Clark, S. J. (2024). Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer. BJUI Compass, 5(12), 1299-1306. https://doi.org/10.1002/bco2.445

Vancouver

Pidsley R, Lam D, Qu W, Stricker P, Kench JG, Horvath LG, et al. Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer. BJUI Compass. 2024;5(12):1299-1306. doi:10.1002/bco2.445

BibTeX
@article{Pidsley2024,
  author = {Pidsley, Ruth and Lam, Dilys and Qu, Wenjia and Stricker, Phillip and Kench, James G and Horvath, Lisa G and Clark, Susan J},
  title = {Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer},
  journal = {BJUI Compass},
  year = {2024},
  volume = {5},
  number = {12},
  pages = {1299--1306},
  doi = {10.1002/bco2.445}
}
Start for free →